The peptide therapeutics contract API manufacturing market is experiencing steady growth at a 7.3% CAGR, driven primarily by the increasing preference of pharmaceutical companies to outsource non-core activities[reference:33]. This allows biotech firms to redirect capital towards R&D and clinical trials while leveraging the specialized infrastructure of established CDMOs. The market, valued at $2.89 billion in 2025, is projected to reach $4.11 billion by 2030[reference:34].
One critical factor driving this growth is the regulatory complexity associated with peptide manufacturing. CDMOs offer extensive experience in navigating FDA and EMA guidelines, ensuring that peptide APIs meet stringent quality standards. The ability to handle complex sequences and hazardous reagents safely also makes outsourcing a more viable option than in-house production for many mid-sized companies. Key industry players include Thermo Fisher Scientific, Lonza Group, WuXi AppTec, Cambrex, ChemPartner, and GenScript Biotech[reference:35].
The volatility of raw material supply chains has made strategic partnerships with CDMOs essential for ensuring consistent and reliable peptide API supply. Major companies are focusing on innovative solutions such as continuous flow synthesis platforms to streamline production and manage the increasing complexity of drug development[reference:36]. Continuous flow synthesis integrates reaction, separation, concentration, and crystallization into a single uninterrupted process with real-time in-line monitoring, enabling precise, scalable, and efficient manufacturing[reference:37].
The rising prevalence of diabetes is a primary driver of growth in this market[reference:38]. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels, and the increasing prevalence is largely driven by rising obesity rates. Peptide therapeutics rely on contract API manufacturing to enable large-scale production of hormone-mimicking drugs, which enhance insulin secretion and help control glucose levels[reference:39]. In England, type 2 diabetes prevalence among adults aged 17 and older reached 7% in March 2024[reference:40].
Recent industry developments highlight the strategic importance of this market. In December 2024, Novo Holdings A/S acquired Catalent Inc. for $16.5 billion to optimize the development and delivery of transformative therapies[reference:41]. In May 2023, SynCrest Inc. launched its GMP-compliant Naruto Plant equipped with a continuous flow synthesis platform for peptide and nucleotide API production, allowing rapid manufacturing of over 100 types of non-natural amino acids and high-purity special amidites[reference:42]. These investments underscore the growing recognition of peptide API manufacturing as a critical component of the pharmaceutical supply chain.